Endo Pharmaceuticals Holdings News

FDA concerns about the safety of two testosterone boosters from Endo Pharmaceuticals may delay their approval, but safety concerns haven't kept testosterone sales from increasing 25 percent in the past year , according Business Week .

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference , today announced that Noah D. Beerman has joined the company as its new President and Chief Executive Officer.

Bioniche Life Sciences Inc.'s first-quarter loss more than doubled as revenues slightly dipped, the biotechnology company said Friday.

Bioniche Life Sciences Inc. , a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 first quarter, ended September 30, 2009.

Penwest Pharmaceuticals Co. November 5, 2009 11:00 am ET Executives Jennifer Good - President and CEO Frank Muscolo - Corporate Controller and Chief Accounting Officer Analysts David Watson Scott Henry - Roth Capital Presentation Operator At this time, I would like to welcome everyone to the Penwest third quarter 2009 financial results conference ...

BUYINS.NET, www.buyins.net, a provider of unique trading technologies, released a report on October 27, 2009 at 10:32 am PDT stating that Endo Pharmaceuticals was expected to be higher after its earnings were released before the open on Thursday, October 29, 2009.

When Endo Pharmaceuticals acquired two experimental testosterone products earlier this year, CEO David P. Holveck predicted that safety issues might delay approval by the U.S. Food & Drug Administration.

Endo Pharmaceuticals today announced that it received a Complete Response letter from the U.S. Food and Drug Administration regarding the New Drug Application for Fortesta 2% Gel for men diagnosed with low testosterone , also known as hypogonadism.

Shares in ProStrakan, the Borders-based speciality pharmaceutical group, plunged almost 5% yesterday after it emerged US health regulators delayed approval of its cure-all for the male menopause.

Endo Pharmaceuticals said Monday it expects to respond to the Food and Drug Administration's questions about the company's new drug application for the low testosterone treatment Fortesta by mid-2010. Fortesta is an experimental gel product for men diagnosed with low testosterone, also known as hypogonadism.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Pennsylvania Bio , the statewide Association representing Pennsylvania's biosciences community, today announced the appointment of two new members to its Board of Directors: Dr.

Endo Pharmaceuticals By Jefferies & Co. WE ARE ASSUMING coverage of Endo Pharmaceuticals from Jefferies analyst David Windley with a Buy rating and a $30 price target.

CHADDS FORD, Pa. Drug maker Endo Pharmaceuticals announced the introduction of a drug that it says fills an unmet need as a treatment for bladder cancer.

Ilhavo, Portugal a ' 08-09-2009 a ' SADIF Investment Analytics, announces a new summary due diligence report covering Endo Pharmaceuticals .

VALSTAR represents a new treatment option for these patients who may otherwise have exhausted all other FDA-approved treatment alternatives, including BCG.

The FDA extended its review period to Dec. 2. The review had been scheduled to end Sept.

Main Category: Endocrinology Also Included In: Regulatory Affairs / Drug Approvals ; Pharma Industry / Biotech Industry Article Date: 03 Sep 2009 - 3:00 PDT Endo Pharmaceuticals announced that it has been informed by the U.S. Food and Drug Administration that the agency has extended its review period for its long-acting testosterone undecanoate ...

Drug stock catalyst junkies take note: Tomorrow the U.S. Food and Drug Administration is expected to issue an approval decision on Endo Pharmaceuticals' long-acting injectable testosterone drug, Nebido.

A panel of cancer experts convened by the Food and Drug Administration is meeting right now outside Washington, D.C. to review a leukemia drug from biotech firm Genzyme .